Kyverna Therapeutics, a cell therapy company engineering a new class of therapies for serious autoimmune diseases, has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures.

Additional investors included the company's founding investors Westlake Village BioPartners, Vida Ventures, and Gilead Sciences, with new investors RTW Investments, LP, CAM Capital, Insight Partners, HealthCor, LYFE Capital, Intellia Therapeutics, Argentum Peak, Hudson Bay Capital, and jVen Capital.